Efficacy of early biopsy in kidney allograft recipients with delayed graft function

Transplant Proc. 2007 Jul-Aug;39(6):1803-4. doi: 10.1016/j.transproceed.2007.05.015.

Abstract

It is accepted that kidney transplants that display delayed graft function (DGF) show poorer survival and function, particularly when an acute rejection episode (ARE) occurs. A diagnostic biopsy to establish the reason for DGF, or acknowledge an ARE, even if borderline, can improve short- and long-term graft survivals. From January 2002 to September 2006 we retrospectively evaluated 358 kidney transplant recipients. We performed a biopsy to evaluate the cause of DGF in all patients who required dialysis, or had serum creatinine levels that increased, remained unchanged, or decreased less than 10% per day on three consecutive days during the first week after transplantation. An ARE was found in 18.8% (n = 19) of the biopsies. Early biopsy for patients with DGF is a safe method that allows uncovering of an ARE that would otherwise be undetected. The immediate recognition and treatment of rejection episodes can certainly increase long-term survival and function of renal transplants.

MeSH terms

  • Antilymphocyte Serum / therapeutic use
  • Biopsy
  • Graft Rejection / epidemiology
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Kidney Function Tests
  • Kidney Transplantation / pathology*
  • Kidney Transplantation / physiology*
  • Time Factors
  • Transplantation, Homologous / pathology
  • Transplantation, Homologous / physiology
  • Treatment Outcome

Substances

  • Antilymphocyte Serum
  • Immunosuppressive Agents